Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kathleen Batty
Observed names:
K. Batty,
Kathleen M. Batty
Institutions:
University of Auckland,
Auckland UniServices (New Zealand)
Observed institutions:
University of Auckland,
Royal North Shore Hospital,
UNSW Sydney,
Melanoma Institute Australia,
Auckland UniServices (New Zealand)
ORCID:
0000-0002-4451-2548
Observed ORCID:
0000-0002-4451-2548
OpenAlex ID:
A5036010292
COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals
2024
·
K. Faksova
, D. Walsh
, et al.
·
Vaccine
·
260
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
2022
·
Prachi Bhave
, Tasnia Ahmed
, et al.
·
Journal for ImmunoTherapy of Cancer
·
70
PDF
The Potential of panHER Inhibition in Cancer
2015
·
Xiaochun Wang
, Kathleen M. Batty
, et al.
·
Frontiers in Oncology
·
40
PDF
Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review
2023
·
Bryan Khuong Le
, Patrick McGarrah
, et al.
·
Clinical Genitourinary Cancer
·
13
Metastatic primary breast neuroendocrine neoplasms: a case series
2022
·
Kathleen Batty
, Amelia M. Taylor
, et al.
·
Internal Medicine Journal
·
6
Interim phase 1 results for SQ3370 in advanced solid tumors.
2022
·
Sant P. Chawla
, Kathleen Batty
, et al.
·
Journal of Clinical Oncology
·
4
Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.
2020
·
Victoria Atkinson
, Kathleen Batty
, et al.
·
Journal of Clinical Oncology
·
4
547P Early pharmacokinetic data from a phase I study of SQ3370 in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform
2021
·
V. Subbiah
, V. Bhadri
, et al.
·
Annals of Oncology
·
3
1047P Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
2021
·
P. Bhave
, T. Ahmed
, et al.
·
Annals of Oncology
·
3
Abstract OT1-02-01: 4CAST: A Phase 1b dose exploration and dose expansion, open-label study evaluating the safety and efficacy of INO-464 in combination with Chemotherapy in patients with metASTatic breast cancer
2023
·
Rachel F. Dear
, Kathleen Batty
, et al.
·
Cancer Research
·
1
367 Pharmacokinetic and immunologic data from a phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform
2021
·
Vivek Bhadri
, Vivek Subbiah
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract CT177: SQ3370 in advanced solid tumors: Interim phase 1 results
2022
·
Sant P. Chawla
, Kathleen Batty
, et al.
·
Cancer Research
Pembrolizumab as adjuvant therapy in a patient with Lynch syndrome with synchronous mixed clear cell carcinoma of ovarian origin and endometroid endometrial carcinoma
2021
·
Kathleen Batty
, Minmin Li
, et al.
·
BMJ Case Reports
Show more works
View as search
Works count:
13
Citation count:
405
H-index:
5
I10-index:
4
Year
Topic
Type